超声引导下穿刺硬化治疗肝肾囊肿患者临床疗效研究*

doi:10.3969/j.issn.1672-5069.2022.03.034

摘要/Abstract

摘要： 目的探讨超声引导下穿刺硬化治疗肝肾囊肿患者的临床疗效。方法 2019年1月～2020年12月我院收治的肝肾囊肿患者72例,其中36例在超声引导下穿刺注射无水乙醇治疗,另36例注射聚桂醇治疗。比较两组临床疗效、囊肿体积缩小率和不良反应发生率。结果在术后6个月超声复查,聚桂醇治疗组囊肿消失或明显缩小发生率为94.4%,与无水乙醇治疗组的91.7%比,无显著性差异(P>0.05);在术后1 m、3 m和6 m,聚桂醇治疗组囊肿体积缩小率分别为(67.5±8.1)%、(81.6±5.5)%和(95.2±4.9)%,显著高于乙醇治疗组【分别为(53.9±6.4)%、(73.2±4.7)%和(85.6±3.5)%,P＜0.05】;聚桂醇治疗组术后发热、醉酒样反应和恶性呕吐等不良反应发生率为8.3%,显著低于无水乙醇治疗组的27.8%(P＜0.05)。结论在超声引导下穿刺注射聚桂醇或无水乙醇硬化治疗肝肾囊肿患者疗效较好,但注射聚桂醇可提高囊肿体积缩小率,减少不良反应的发生。

关键词: 肝囊肿, 肾囊肿, 聚桂醇, 无水乙醇, 超声引导, 治疗

Abstract: Objective The aim of this study was to investigate the efficacy of lauromacrogol or anhydrous ethanol sclerotherapy under the guidance of color Doppler ultrasound (US) in patients with liver-kidney cysts. Methods 72 patients with liver-kidney cysts were encountered in our hospital between January 2019 and December 2020, and they all underwent cyst puncture under US guidance and sclerotheray. Out of them, 36 patients had lauromacrogol, and another 36 patients had ethanol sclerotherapy. They all were followed-up for six months. Results At the end of six month follow-up, the disappearance or obvious shrink of liver and kidney cysts in lauromacrogol-treated patients was 94.4%, not significantly different compared to 91.7% in patients with ethanol sclerotherapy(P>0.05); at one, three and six month after operation, the cyst reduction rates in lauromacrogol-treated patients were(67.5±8.1)%, (81.6±5.5)% and (95.2±4.9)%, all significantly lower than [(53.9±6.4)%, (73.2±4.7)% and (85.6±3.5)%, respectively, P＜0.05] in ethanol-treated patients; the incidences of side effects, such as fever, drunkenness-like reaction and nausea in lauromacrogol-treated patients was 8.3%, significantly lower than 27.8%(P＜0.05) in ethanol-treated patients. Conclusion The anhydrous ethanol or lauromacrogol sclerotherapy under US guidance in the treatment of patients with liver-kidney cysts is efficacious, and we recommend lauromacrogol sclerotherapy because of its high reduction rates of cysts and low incidences of adverse reactions.

Key words: Liver cysts, Kidney cyst, Lauromacrogol, Ethanol, Ultrasound guidance, Therapy

江攀, 张惠林, 刘海, 苏娟. 超声引导下穿刺硬化治疗肝肾囊肿患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 439-442.

Jiang Pan, Zhang Huilin, Liu Hai, et al. Disappearance of liver-kidney cysts by lauromacrogol or anhydrous ethanol sclerotherapy under the guidance of color Doppler ultrasound[J]. Journal of Practical Hepatology, 2022, 25(3): 439-442.

参考文献

[1] Gomez A, Wisneski AD, Luu HY,et al. Contemporary management of hepatic cyst disease: Techniques and outcomes at a tertiary hepatobiliary center. J Gastrointest Surg, 2021,25(1):77-84.
[2] Sahin H, Sarioglu FC, Alaygut D, et al. Differentiation of simple renal parenchymal cyst and calyceal diverticulum. Pediatr Int, 2020,62(5):615-623.
[3] Lai S, Jiao B, Wang X,et al. Renal cell carcinoma originating in the free wall of simple renal cyst: Two unusual case reports with literature review. Medicine (Baltimore), 2019,98(16):152-154.
[4] Bernts LHP, Dekker SEI, Soonawala D, et al. Efficacy and safety of selective decontamination of the digestive tract (SDD) to prevent recurrent hepatic cyst infections in polycystic liver disease: a retrospective case series. J Antimicrob Chemother, 2020,1(9):2666-2669.
[5] 祁莉娜, 颜梅, 郭建琴. 腹腔镜下肝囊肿开窗术与超声引导下穿刺介入治疗单纯性肝囊肿患者疗效对比研究. 实用肝脏病杂志, 2019,22(4):581-584.
[6] 袁冰,阎洁羽,王茂强,等. 两种栓塞方法行超选择性肝动脉栓塞术治疗多囊肝病的对比研究. 中华肝胆外科杂志, 2019,25(7):505-508.
[7] 吴为民,吴磊,温立霞,等. 无水乙醇联合聚桂醇治疗弥漫性浸润型静脉畸形一例. 中华整形外科杂志, 2019,35(5):497-501.
[8] 徐琛,李明珠,楼叶琳,等. 超声介入下聚桂醇联合甲氨蝶呤局部注射治疗高龄剖宫产子宫瘢痕妊娠的临床观察. 中华全科医学, 2020,18(4):605-608,633.
[9] 陈灏珠,林果为.实用内科学.北京:人民卫生出版社,2010:2389.
[10] Mallereau CH, Ganau M, Todeschi J, et al. Relapsing-remitting hepatic pseudo-cyst: A great simulator of malfunctioning ventriculoperitoneal shunt. Case report and proposal of a new classification. Neurochirurgie, 2020,66(6):461-465.
[11] 陈肖俊,周琦,王芳,等. 超声引导下经皮穿刺聚桂醇硬化治疗甲状腺囊性和囊实性结节的前瞻性初步研究. 中华耳鼻咽喉头颈外科杂志, 2019,54(1):33-37.
[12] Serrano Á, Sánchez M, Ciappara M, et al. Laparoscopic renal cyst excision: Large simple renal cyst treatment with renal cell carcinoma cells in its wall. Histogenetic considerations and bibliographic review. Arch Esp Urol, 2019,72(4):422-428.
[13] 郑翔,谷丽,郎韧,等. 多囊肾合并多囊肝患者肾移植后肝囊肿反复感染行肝移植一例并文献复习.中华器官移植杂志, 2020,41(8):470-473.
[14] Chen J, Ma X, Xu D, et al. Association between simple renal cyst and kidney damage in a Chinese cohort study. Ren Fail, 2019,41(1):600-606.
[15] 郭庆涛,马超,李明明,等. 改良硬化治疗对Leg型食管胃静脉曲张破裂出血的疗效和安全性.中华消化杂志, 2019,39(6):409-411.
[16] 李海波,李小梅,周少毅,等. 数字减影血管造影引导下硬化治疗四肢肌肉间静脉畸形的疗效分析. 中华小儿外科杂志, 2019,40(10):925-929.
[17] Darvish L, Khezri M, Teshnizi SH, et al. Color Doppler ultrasonography diagnostic value in detection of malignant nodules in cysts with pathologically proven thyroid malignancy: a systematic review and meta-analysis. Clin Transl Oncol, 2019,21(12):1712-1729.
[18] 梁伟,胡伟,沈俊,等. 超声引导下聚桂醇注射治疗肾活检术后大出血一例. 中华肾脏病杂志,2020,36(1):53-55.
[19] Le Daré B, Gicquel T. Therapeutic applications of ethanol: A review. J Pharm Pharm Sci, 2019,22(1):525-535.
[20] Xu S,Rao M,Pu Y, et al. The efficacy of laparoscopic lauromacrogol sclerotherapy in the treatment of simple hepatic cysts located in posterior segments: a refined surgical approach. Ann Palliat Med,2020,9(5):3462-3471.
[21] Xiang J, Linghu E, Chai N. Case of large intra-esophageal bronchogenic cyst treated with lauromacrogol ablation. Dig Endosc,2020,32(3):435.
[22] 余力,蒋天安,杨性安. 无水乙醇和聚桂醇不同使用方式对卵巢子宫内膜异位囊肿疗效的对比研究. 中华超声影像学杂志,2021,30(5):426-431.
[23] 杜晨,柴宁莉,令狐恩强,等. 内镜超声引导下聚桂醇消融治疗胰腺囊性肿瘤长期疗效的前瞻性研究. 中华消化内镜杂志,2020,37(10):696-701.
[24] 陈肖俊,周琦,王芳,等. 超声引导下经皮穿刺聚桂醇硬化治疗甲状腺囊性和囊实性结节的前瞻性初步研究.中华耳鼻咽喉头颈外科杂志,2019,54(1):33-37.
[25] Du C, Chai NL, Linghu EQ, et al. Endoscopic ultrasound-guided injective ablative treatment of pancreatic cystic neoplasms. World J Gastroenterol, 2020,21(23):3213-3224.

超声引导下穿刺硬化治疗肝肾囊肿患者临床疗效研究^*

Disappearance of liver-kidney cysts by lauromacrogol or anhydrous ethanol sclerotherapy under the guidance of color Doppler ultrasound

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郭悦承, 陆伦根. 肝纤维化临床诊断与治疗研究进展[J]. 实用肝脏病杂志, 2022, 25(3): 305-308.
[2]	黄俊榕, 吴昌儒, 吴健林. 恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 327-330.
[3]	邹东花, 秘建威, 李玉苓, 赵森. 阿德福韦酯分别联合恩替卡韦或替诺福韦治疗rtA181V/T单位点突变的慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 331-334.
[4]	柴晓哲, 朱霞峰, 骆成林, 王少峰. 泛基因型与特异基因型DAAs方案精准治疗基因1b型慢性丙型肝炎患者疗效对比分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 355-358.
[5]	胡春霞, 杨娇楠, 张丰晓, 胡敬华. 格卡瑞韦/哌仑他韦治疗基因1b型慢性丙型肝炎患者疗效及安全性分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 359-362.
[6]	陈业京, 陆清平, 顾少颖. 异甘草酸镁与复方甘草酸单胺治疗药物性肝损伤患者疗效比较研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 371-374.
[7]	杨海华, 周聪, 沈国强, 尤晓红, 孟玲. 134例替加环素致药物性肝损伤老年患者临床特征回顾性分析[J]. 实用肝脏病杂志, 2022, 25(3): 375-378.
[8]	王诗淞, 林辉雄, 张泰胜, 董俪雯, 王英霞, 林秋香. 二甲双胍联合达格列净治疗T2DM合并NAFLD患者疗效及血清二肽基肽酶4和C肽变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 379-382.
[9]	沈扬林, 谭可平, 游忠岚, 陈婵, 陆晖, 甘琼萍, 覃国琦, 陆鹏. 血浆置换序贯双重血浆分子吸附系统治疗慢加急性乙型肝炎肝衰竭患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 387-390.
[10]	孙亚男, 曾庆环, 刘远志, 张世斌, 李鹏, 武永乐, 丁惠国. 伴有中/重度食管静脉曲张的慢加急性肝衰竭患者预后危险因素分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 391-394.
[11]	詹惠珍, 杜雅钦, 王松姣. 特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 395-398.
[12]	郭慧雯, 张峰, 肖江强, 张玮, 张明, 邹晓平, 诸葛宇征. 球囊导管闭塞下逆行性静脉栓塞术治疗胃静脉曲张破裂出血患者疗效分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 407-410.
[13]	邱云, 杨玫, 薛红红. TACE联合超声引导下微波消融治疗特殊部位原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 419-422.
[14]	马虎成, 任昊桢, 汤宁, 王帅, 张玉衡, 施晓雷. 机器人与开腹手术治疗肝内胆管细胞癌患者近期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 423-426.
[15]	李文强, 程春霞, 徐冬梅. 腹腔镜开窗引流术与超声引导下穿刺硬化术治疗肝囊肿患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 443-446.